Conversion to everolimus to preserve kidney function in a heart transplant recipient, a personalized approach of immunos uppressive therapy
https://doi.org/10.15825/1995-1191-2018-3-70-74
Abstract
Heart transplantation is the «gold standard» of treatment severe heart failure. Patient survival after heart transplantation has improved dramatically since the availability of calcineurin inhibitor (CNIs). However, nephrotoxicity of CNIs has been largely responsible for the progressive development of renal dysfunction and reduces long-term patient survival. Use mTOR inhibitor in immunosuppressive therapy may improve renal function when everolimus is administered associated with a progressive reduction of CNIs. The purpose of our report is to demonstrate the successful case of conversion of the recipient after heart transplantation to everolimus and to evaluate the effectiveness of this drug during the observation year after heart transplantation.
About the Authors
N. N. KoloskovaRussian Federation
Address: 1, Shchukinskaya st., Moscow, 123182, Russian Federation. Теl. (926) 651-40-64
E. A. Nikitina
Russian Federation
V. M. Zakharevich
Russian Federation
I. I. Muminov
Russian Federation
V. S. Cvan
Russian Federation
V. N. Poptsov
Russian Federation
R. L. Ahmadzai
Russian Federation
D. A. Izotov
Russian Federation
A. O. Shevchenko
Russian Federation
References
1. Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report – 2014; focus theme: retransplantation. J. Heart Lung Transplant. 2014; 33: 996–1008.
2. Manito N, Delgado JF, Crespo-Leiro MG, Arizón JM, Segovia J, González-Vílchez F et al. Twelve-month efficacy and safety of the conversion to everolimus in maintenance heart transplant recipients. World J. Transplant. 2015 Dec. 24; 5 (4): 310–319.
3. The registry of the international society for heart and lung transplantation: thirty- second annual report – 2017. JHLT. 2017 Oct; 36 (10): 1037–1079.
4. Готье СВ. Иммуносупрессия при трансплантации солидных органов. М.: Триада, 2011: 12–17. Gautier SV. Immunosupressiya pri transplantatsii solidnykh organov. M.: Triada, 2011: 12–17.
5. Kobashigawa J.A., Pauly D., Kfoury A et al. Multicenter randomized trial of everolimus vs mycophenolate mofetil in heart transplantation: final 24 month analysis of efficacy and safety. J. Heart Lung Transplant. 2012; 31: S73–S74.
6. González-Vílchez F, Vazquez de Prada JA, Paniagua MJ, Gomez-Bueno M, Arizon JM, Almenar L et al. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization? Int. J. Cardiol. 2014; 171: 15– 23.
7. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N. Engl. J. Med. 1984; 311: 699–705. [PubMed] 22. Cattaneo D, Perico N, Gaspari F, Remuzzi G. Nephrotoxic aspects of cyclosporine. Transplant. Proc. 2004; 36: 234S–239S.
8. Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation. 2010; 89: 864–872.
9. Gullestad L, Mortensen SA, Eiskjær H, Riise GC, Mared L, Bjørtuft O et al. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Transplantation. 2010; 90: 1581–1589.
10. Hummel M. Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference. J. Heart Lung Transplant. 2005; 24: 196.
11. Bocchi EA, Ahualli L, Amuchastegui M et al. Recommendations for use of everolimus after heart transplantation: results from a Latin-American Consensus Meeting. Transplant. Proc. 2006; 38: 937.
12. Lehmkuhl H, Ross H, Eisen H et al. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure. Transplant. Proc. 2005; 37: 4145.
13. Fiocchi R, Frigerio M, Parisi F et al. Guidelines for everolimus introduction in stable heart transplant. Trapianti. 2006; 3: 107.
14. Kuypers DRJ, Le Meur Ya, Cantarovich M et al. The Transplantation Society (TTS) Consensus Group on TDM of MPA. Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation. Clin. J. Am. Soc. Nephrol. 2010; 5: 341–358.
15. Mohammadpour N, Elyasi S, Vahdati N. A Review on Therapeutic Drug Monitoring of Immunosuppressant Drugs. Iranian Journal of Basic Medical Sciences. 2011; 14 (6): 485–498.
Review
For citations:
Koloskova N.N., Nikitina E.A., Zakharevich V.M., Muminov I.I., Cvan V.S., Poptsov V.N., Ahmadzai R.L., Izotov D.A., Shevchenko A.O. Conversion to everolimus to preserve kidney function in a heart transplant recipient, a personalized approach of immunos uppressive therapy. Russian Journal of Transplantology and Artificial Organs. 2018;20(3):70-74. (In Russ.) https://doi.org/10.15825/1995-1191-2018-3-70-74